Docetaxel AHP 80mg Inj. 1`s

A qualified oncology team administers it as an intravenous infusion after mandatory steroid premedication.

Docetaxel AHP 80mg Injection Ingredients and Usage

Docetaxel AHP 80mg Injection contains docetaxel, a semi-synthetic taxane belonging to the antimicrotubule anticancer drug class. Oncologists prescribe it for locally advanced or metastatic breast cancer, often combined with doxorubicin and cyclophosphamide in the adjuvant setting.

Docetaxel AHP 80mg Injection also treats non small cell lung cancer, metastatic castration resistant prostate cancer with prednisone, gastric adenocarcinoma, and squamous cell head and neck cancer. Treatment is given in defined cycles every three weeks under specialist supervision.

How Does Docetaxel AHP 80mg Injection Work?

Docetaxel binds to tubulin and promotes the assembly of stable microtubules while blocking their normal disassembly. Microtubules must reorganize dynamically for a cell to complete division.

By locking microtubules in place, Docetaxel AHP 80mg Injection arrests cancer cells during mitosis and prevents them from dividing. This disruption triggers programmed cell death, slowing or stopping tumor growth across the cancers it treats.

Docetaxel AHP 80mg Injection Side Effects

Docetaxel AHP 80mg Injection commonly causes blood count changes and fluid related side effects, which steroid premedication helps reduce.

• Low white blood cell count, raising infection risk

• Fluid retention and swelling

• Hair loss

• Fatigue

• Nausea and mouth sores

• Numbness or tingling in hands and feet

• Nail changes

Warnings

• Docetaxel AHP 80mg Injection carries a boxed warning covering toxic deaths, hepatotoxicity, neutropenia, hypersensitivity reactions, and fluid retention; treatment related death risk rises with abnormal liver function and higher doses.

• Liver function tests must be checked before each treatment cycle; avoid use if bilirubin exceeds the upper limit of normal or liver enzymes are significantly elevated.

• Do not administer if the neutrophil count is below 1,500 cells per cubic millimeter; frequent blood counts are required to monitor for severe neutropenia.

• Severe hypersensitivity reactions, including rare fatal anaphylaxis, can occur even after steroid premedication; treatment must be given where facilities for managing anaphylaxis are available.

• All patients require oral corticosteroid premedication, typically dexamethasone, for three days starting the day before infusion to reduce fluid retention and hypersensitivity risk.

• Docetaxel AHP 80mg Injection can cause fetal harm and is contraindicated in pregnancy; effective contraception is required during treatment.

• Neutropenic enterocolitis can develop rapidly and may be fatal; monitor closely for abdominal pain, fever, or diarrhea during neutropenic periods.

Docetaxel AHP 80mg Injection Storage Conditions

Store Docetaxel AHP 80mg Injection in a dry, clean, well-ventilated area at room temperature between 15°C and 25°C, or up to 30°C. Keep the vial in its original packaging until immediately before use. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.